Technology area: Biotechnology & Pharmaceuticals
14 pending office actions • 9 art units • 14 examiners • 0 of 14 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Gritstone Bio Inc. maintains 14 pending office actions focused in the Biotechnology & Pharmaceuticals sector. The portfolio is handled by 14 distinct examiners, matching the total number of pending actions exactly. This distribution indicates that no single examiner is currently managing multiple active files for the company. These matters are distributed across 9 distinct art units, showing some concentration of technology despite the high number of individual examiners. BARRY A CHESTNUT is the busiest examiner for the company, yet holds only 1 pending office action.
This suggests that the prosecution strategy involves navigating a variety of technical niches within the broader pharmaceutical landscape. For a practitioner, this decentralized examiner base requires a flexible approach to prosecution, as each matter will be subject to the unique tendencies of a different reviewer. The concentration in 9 art units suggests that while the examiners differ, the legal and technical hurdles may be similar across several cases. Managing 14 distinct examiners simultaneously requires significant coordination to ensure that arguments made in one case do not negatively impact others. The presence of 14 pending office actions across such a wide range of examiners highlights the complexity of the company's current patenting efforts.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 5 (36%) |
| §103 only | 2 (14%) |
| §102 only | 1 (7%) |
| §112 only | 1 (7%) |
| Double-patenting + other | 2 (14%) |
| Multi-statute (no §101) | 3 (21%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHESTNUT, BARRY A | 1 | 73.9% | +6.3% |
| GODDARD, LAURA B | 1 | 50.8% | +13.6% |
| GRIZER, CASSANDRA SENN | 1 | 70.0% | +48.0% |
| JADHAO, SAMADHAN JAISING | 1 | 46.2% | +47.0% |
| DAHLE, CHUN WU | 1 | 50.2% | +51.1% |
| LEE, HOI YAN NMN | 1 | 37.5% | +76.2% |
| LIPPOLIS, ALEXANDRA ROSE | 1 | 47.2% | +63.6% |
| CHEN, STACY BROWN | 1 | 66.1% | +40.4% |
| LEE, YIE CHIA | 1 | 69.2% | +46.6% |
| VIVLEMORE, TRACY ANN | 1 | 73.0% | +6.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16975823 | Neoantigen Identification with Pan-Allele Models | BAILEY, STEVEN WILLIAM | 45d overdue |
| 18658604 | SELF-AMPLIFYING RNA COMPOSITIONS AND METHODS OF USE THEREOF | CHESTNUT, BARRY A | — |
| 18504497 | REDUCING JUNCTION EPITOPE PRESENTATION FOR NEOANTIGENS | GODDARD, LAURA B | — |
| 18272087 | HOMOLOGOUS ADENOVIRAL VACCINATION | GRIZER, CASSANDRA SENN | — |
| 17817312 | HIV ANTIGENS AND MHC COMPLEXES | LIPPOLIS, ALEXANDRA ROSE | — |
| 17744354 | ANTIGEN-BINDING PROTEINS TARGETING SHARED NEOANTIGENS | LEE, YIE CHIA | — |
| 17581788 | NEOANTIGEN IDENTIFICATION USING HOTSPOTS | WOITACH, JOSEPH T | — |
| 17436367 | IDENTIFICATION OF NEOANTIGENS WITH MHC CLASS II MODEL | NGUYEN, PETER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18048407 | CAPPING COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | LEE, HOI YAN NMN | 31d overdue |
| 18504497 | REDUCING JUNCTION EPITOPE PRESENTATION FOR NEOANTIGENS | GODDARD, LAURA B | — |
| 18272087 | HOMOLOGOUS ADENOVIRAL VACCINATION | GRIZER, CASSANDRA SENN | — |
| 18255539 | COMPOSITIONS AND METHODS OF USE THEREOF | JADHAO, SAMADHAN JAISING | — |
| 18018400 | ENGINEERED MULTI-SPECIFIC ANTIBODIES AND RELATED METHODS OF USE AND MANUFACTURE | DAHLE, CHUN WU | — |
| 17817312 | HIV ANTIGENS AND MHC COMPLEXES | LIPPOLIS, ALEXANDRA ROSE | — |
| 17838114 | DURABLE VACCINATION | CHEN, STACY BROWN | — |
| 17744354 | ANTIGEN-BINDING PROTEINS TARGETING SHARED NEOANTIGENS | LEE, YIE CHIA | — |
| Art Unit | Apps |
|---|---|
| 1672 | 4 |
| 1642 | 2 |
| 1687 | 2 |
| 1641 | 1 |
| 1693 | 1 |
| 1637 | 1 |
| 1638 | 1 |
| 1685 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18658604 | SELF-AMPLIFYING RNA COMPOSITIONS AND METHODS OF USE THEREOF | CHESTNUT, BARRY A | 1672 | §103§112 | Non-Final OA | — | Pending | May 08, 2024 |
| 18504497 | REDUCING JUNCTION EPITOPE PRESENTATION FOR NEOANTIGENS | GODDARD, LAURA B | 1642 | §101§103§112DP | Non-Final OA | — | Pending | Nov 08, 2023 |
| 18272087 | HOMOLOGOUS ADENOVIRAL VACCINATION | GRIZER, CASSANDRA SENN | 1672 | §103§112 | Non-Final OA | — | Pending | Jul 12, 2023 |
| 18255539 | COMPOSITIONS AND METHODS OF USE THEREOF | JADHAO, SAMADHAN JAISING | 1672 | §102§103§112DP | Non-Final OA | — | Pending | Jun 01, 2023 |
| 18018400 | ENGINEERED MULTI-SPECIFIC ANTIBODIES AND RELATED METHODS OF USE AND MANUFACTURE | DAHLE, CHUN WU | 1641 | §112 | Non-Final OA | — | Pending | Jan 27, 2023 |
| 18048407 | CAPPING COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | LEE, HOI YAN NMN | 1693 | §103Other | Final Rejection | 31d overdue | Pending | Oct 20, 2022 |
| 17817312 | HIV ANTIGENS AND MHC COMPLEXES | LIPPOLIS, ALEXANDRA ROSE | 1637 | §103§112 | Non-Final OA | — | Pending | Aug 03, 2022 |
| 17838114 | DURABLE VACCINATION | CHEN, STACY BROWN | 1672 | §103§112DP | Final Rejection | — | Pending | Jun 10, 2022 |
| 17744354 | ANTIGEN-BINDING PROTEINS TARGETING SHARED NEOANTIGENS | LEE, YIE CHIA | 1642 | §101§102§103§112 | Non-Final OA | — | Pending | May 13, 2022 |
| 17736738 | SHARED NEOANTIGEN VACCINES | VIVLEMORE, TRACY ANN | 1638 | §102Other | Final Rejection | 141d overdue | Pending | May 04, 2022 |
| 17581788 | NEOANTIGEN IDENTIFICATION USING HOTSPOTS | WOITACH, JOSEPH T | 1687 | §101§112Other | Non-Final OA | — | Pending | Jan 21, 2022 |
| 17436367 | IDENTIFICATION OF NEOANTIGENS WITH MHC CLASS II MODEL | NGUYEN, PETER | 1685 | §101§103DP | Final Rejection | — | Pending | Sep 03, 2021 |
| 17433817 | SELECTION OF T CELL RECEPTORS | FAUST, AMBER KATHLEEN | 1643 | §103 | Final Rejection | — | Pending | Aug 25, 2021 |
| 16975823 | Neoantigen Identification with Pan-Allele Models | BAILEY, STEVEN WILLIAM | 1687 | §101§103§112DP | Final Rejection | 45d overdue | Pending | Aug 26, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGritstone Bio Inc. has 14 pending office actions as of October 2026, spread across 9 art units and 14 examiners.
Barry A Chestnut has the most, with 1 of Gritstone Bio Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
